A drug problem


Alibaba's health woes show its Midas touch has limits. A unit of the Chinese e-commerce giant has suffered a run-in with mainland regulators. Though shares of the Hong Kong-listed Alibaba Health Information Technology soared when Alibaba took control last year, reality has proved less exciting.

It's a reminder that even boss Jack Ma can't cure investors' loss of faith. China's food and drug regulator has suspended an electronic drug monitoring system as it overhauls pharmaceutical regulations. That's a big blow for.

This article is no longer available in our repository.

There could be multiple reasons for this.